Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
Amount Raised
$147 Million
Round Type
Series B
CarmelBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnology ResearchInvestors
Description
Sudo Biosciences announced the second close of its upsized Series B financing, bringing the total raised in the round to $147M. The funding will be used to advance two investigational TYK2 candidates into the clinic this year, including a potential first and best-in-class brain-penetrant TYK2 therapeutic for multiple sclerosis, Alzheimer’s Disease, and ALS, as well as a potential first and best-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases.
Quick answer
Sudo Biosciences raised $147 Million in a Series B round, dated February 13, 2024. Investors: Dementia Discovery Fund, Velosity Capital, Eventide Asset Management, Monograph Capital, Surveyor Capital, Frazier Life Sciences, Sanofi Ventures and The Rise Fund. Sudo Biosciences is based in Carmel, Indiana, United States.
- How much did Sudo Biosciences raise?
- Sudo Biosciences raised $147 Million in a Series B round on February 13, 2024.
- Who invested in Sudo Biosciences?
- Dementia Discovery Fund, Velosity Capital, Eventide Asset Management, Monograph Capital, Surveyor Capital, Frazier Life Sciences, Sanofi Ventures and The Rise Fund are named as investors in this round.
- What does Sudo Biosciences do?
- Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 inhibitors to transform the treatment of immune-mediated diseases.
- Where is Sudo Biosciences based and how big is it?
- Sudo Biosciences is based in Carmel, Indiana, United States. Fundz records about 24 employees.
- Who are the decision-makers at Sudo Biosciences?
- Fundz holds 1 contact at Sudo Biosciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Sudo Biosciences that raised within 45 days of this round, from Fundz verified event records.
- AEON Biopharma raised $15M (Convertible Note) on March 21, 2024.
- Adipo Therapeutics raised $1.9M (Seed) on March 7, 2024.
- Crinetics Pharmaceuticals raised $350M on March 1, 2024.
- Parabilis Medicines raised $145M (Series E) on March 1, 2024.
- Denali Therapeutics raised $500M on February 29, 2024.
- vTv Therapeutics Inc. raised $51M on February 27, 2024.
Who to call at Sudo Biosciences, and when
A new round usually means Sudo Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Sudo Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sudo Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sudo Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sudo Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSudo Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.